Active Ingredient History
Diazoxide is a drug which was approved by FDA for the treatment of secondary hyperinsulinemia. The drug exerts its action by binding to SUR1 subunit of ATP-sensitive potassium channel that leads to the channel opening. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hyperinsulinism (approved 1976)
Blood Glucose (Phase 2)
Craniopharyngioma (Phase 3)
Depression (Phase 1/Phase 2)
Diabetes Mellitus (Phase 2/Phase 3)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetes Mellitus, Type 2 (Phase 2)
Gestational Age (Phase 2/Phase 3)
Glucose Metabolism Disorders (Phase 2)
Hyperinsulinism (Phase 2)
Hypoglycemia (Phase 4)
Infant, Newborn, Diseases (Phase 2/Phase 3)
Myocardial Stunning (Phase 1)
Obesity (Phase 2)
Pancreatic Neoplasms (Phase 4)
Pituitary Diseases (Phase 3)
Pregnancy in Diabetics (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
